Results 121 to 130 of about 15,279 (220)

Immune persistence after different polio sequential immunization schedules in Chinese infants

npj Vaccines
Trivalent oral poliovirus vaccine (tOPV) has been withdrawn and instead an inactivated poliovirus vaccine (IPV) and bivalent type 1 and type 3 OPV (bOPV) sequential immunization schedule has been implemented since 2016, but no immune persistence data are
Ting Zhao, Jing Li, Teng Huang, Zhi-Fang Ying, Yan-Chun Che, Zhi-Mei Zhao, Yu-Ting Fu, Jun-Hui Tao, Qing-Hai Yang, Ding-Kai Wei, Guo-Liang Li, Li Yi, Yu-Ping Zhao, Hong-Bo Chen, Jian-Feng Wang, Rui-Ju Jiang, Lei Yu, Wei Cai, Wei Yang, Ming-Xue Xie, Qiong-Zhou Yin, Jing Pu, Li Shi, Chao Hong, Yan Deng, Lu-Kui Cai, Jian Zhou, Yu Wen, Hong-Sen Li, Wei Huang, Zhao-Jun Mo, Chang-Gui Li, Qi-Han Li, Jing-Si Yang   +33 more
doaj   +1 more source

Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine. [PDF]

Vaccines (Basel), 2022
Manukyan H, Wahid R, Ansari A, Tritama E, Macadam A, Konz J, Chumakov K, Laassri M.   +7 more
europepmc   +1 more source

Assessment of open data kit mobile technology adoption to enhance reporting of supportive supervision conducted for oral poliovirus vaccine supplementary immunization activities in Nigeria, March 2017-February 2020. [PDF]

Pan Afr Med J, 2023
Bammeke P, Erbeto T, Aregay A, Kamran Z, Adamu US, Damisa E, Usifoh N, Nsubuga P, Waziri N, Bolu O, Dagoe E, Shuaib F.   +11 more
europepmc   +1 more source

Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. [PDF]

Vaccine, 2023
Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM.   +4 more
europepmc   +1 more source

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.

Vaccine, 2023
Harutyunyan V, Quddus A, Pallansch M, Zipursky S, Woods D, Ottosen A, Vertefeuille J, Lewis I.   +7 more
europepmc   +1 more source

A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States. [PDF]

Risk Anal, 2021
Thompson KM, Kalkowska DA, Badizadegan K.   +2 more
europepmc   +1 more source

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes [PDF]

, 2015

core   +1 more source

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China. [PDF]

Lancet Reg Health West Pac, 2023
Tang X, Xiao Y, Deng X, Zhou Y, Chen H, Yan R, Zhu Y, Wang S, Wang H, Zhu X, Luo L, Liu Y, Yin Z, Zhang G, Chen Z, Jiang J, Yang X, He H.   +17 more
europepmc   +1 more source

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials. [PDF]

J Infect Dis, 2022
Gast C, Bandyopadhyay AS, Sáez-Llorens X, De Leon T, DeAntonio R, Jimeno J, Aguirre G, McDuffie LM, Coffee E, Mathis DL, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, Fix A, Konz J, Clemens R, Costa Clemens SA, Rüttimann R.   +19 more
europepmc   +1 more source

Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns. [PDF]

Clin Infect Dis
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Weiner JA, Ackerman ME, Modlin JF, Sajjad OM, Arita M, Gast C, Mainou BA, Zaman K, Hoque M, Rana S, Bandyopadhyay AS, Wright PF.   +15 more
europepmc   +1 more source